Boswellia
An Ayurvedic resin extract (frankincense). Boswellic acids inhibit 5-lipoxygenase and dampen inflammation. The strongest clinical evidence is for knee osteoarthritis pain (a 2020 meta-analysis of 7 RCTs); smaller trials support ulcerative colitis and brain-tumor edema. Generally well tolerated.
Quick decision guide
May help most
Adults with knee osteoarthritis pain looking for a botanical with reasonable trial evidence and a favorable safety profile.
Common dosing range
300–400 mg standardized extract 2–3× daily for OA (100–250 mg/day of AKBA-enriched 5-Loxin); higher doses (1,200–3,600 mg/day) for IBD and cerebral edema research.
When to expect effects
1–2 weeks for pain; 4+ weeks for full OA effect.
Watch out for
May increase bleeding risk with anticoagulants; rare hepatotoxicity reports; can interact with CYP-metabolized drugs.
Evidence snapshot
What is it
Boswellia refers to gum resin extracts from Boswellia trees, primarily Boswellia serrata (Indian frankincense). The active compounds are boswellic acids, used in traditional Ayurvedic medicine and modern supplements for inflammatory and joint conditions.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
Knee osteoarthritis pain and function Good Evidence | WOMAC pain ↓14 points, VAS ↓8 mm vs placebo at 4–12 weeks; effects detectable by day 7 with AKBA-enriched extracts | Adults with knee OA who tolerate oral capsules and want a daily long-term option | 1–4 weeks |
Ulcerative colitis (mild–moderate) Limited Evidence | Remission rates comparable to sulfasalazine in small open trials; modern confirmatory RCTs lacking | Adults with mild ulcerative colitis seeking an adjunct under gastroenterology supervision | 6 weeks (trial duration) |
Asthma adjunctive therapy Limited Evidence | 70% vs 27% symptom improvement at 6 weeks in a single small RCT | Adults with mild persistent asthma curious about an anti-inflammatory adjunct alongside (not instead of) inhaled controller | 6 weeks |
Radiation-induced cerebral edema (brain tumors) Limited Evidence | ≥75% edema reduction in 60% vs 26% placebo on MRI | Brain-tumor patients undergoing radiotherapy under oncology supervision | During radiotherapy course |
Rheumatoid arthritis Limited Evidence | Modest symptom improvement; not consistently demonstrated as monotherapy | RA patients on stable DMARDs interested in a botanical adjunct for residual joint symptoms | 4–12 weeks |
Knee osteoarthritis pain and function
- Effect
- WOMAC pain ↓14 points, VAS ↓8 mm vs placebo at 4–12 weeks; effects detectable by day 7 with AKBA-enriched extracts
- Best fit
- Adults with knee OA who tolerate oral capsules and want a daily long-term option
- Time
- 1–4 weeks
Ulcerative colitis (mild–moderate)
- Effect
- Remission rates comparable to sulfasalazine in small open trials; modern confirmatory RCTs lacking
- Best fit
- Adults with mild ulcerative colitis seeking an adjunct under gastroenterology supervision
- Time
- 6 weeks (trial duration)
Asthma adjunctive therapy
- Effect
- 70% vs 27% symptom improvement at 6 weeks in a single small RCT
- Best fit
- Adults with mild persistent asthma curious about an anti-inflammatory adjunct alongside (not instead of) inhaled controller
- Time
- 6 weeks
Radiation-induced cerebral edema (brain tumors)
- Effect
- ≥75% edema reduction in 60% vs 26% placebo on MRI
- Best fit
- Brain-tumor patients undergoing radiotherapy under oncology supervision
- Time
- During radiotherapy course
Rheumatoid arthritis
- Effect
- Modest symptom improvement; not consistently demonstrated as monotherapy
- Best fit
- RA patients on stable DMARDs interested in a botanical adjunct for residual joint symptoms
- Time
- 4–12 weeks
Evidence for 5 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
Knee osteoarthritis pain and function
Supplement benefitThe strongest evidence base for boswellia. A 2020 meta-analysis of 7 RCTs (n=545) found significant reductions in WOMAC pain (WMD -14.22) and VAS pain (WMD -8.33) versus control at 100–250 mg/day for at least 4 weeks. The pivotal Sengupta 2008 trial of 5-Loxin (AKBA 30%) showed significant pain and function improvement starting at day 7 in the 250 mg group, with reductions in synovial matrix metalloproteinase-3 of 46% by day 90. Effect sizes are comparable to short-term oral NSAIDs but with better GI tolerability.
Bottom line: One of the better-supported botanicals for joint pain. Worth a 4–8 week trial at 100–250 mg/day AKBA-enriched or 300 mg 3×/day standardized extract.
Ulcerative colitis (mild–moderate)
Disease adjunctGupta et al., 1997 RCT in 40 UC patients showed 6 weeks of Boswellia gum resin 350 mg TID achieved remission in 82% vs 75% with sulfasalazine (statistically comparable). A small Crohn's disease trial showed equivalence to mesalazine. Trials are small and old; modern IBD guidelines still treat boswellia as adjunctive rather than first-line. Mechanism (5-LOX inhibition) is plausible for IBD inflammation.
Bottom line: Promising adjunctive option for mild UC; don't replace proven mesalazine, steroids, or biologics without your GI doctor's input.
Asthma adjunctive therapy
Disease adjunctA 1998 double-blind RCT (Gupta et al.) in 40 patients with bronchial asthma found Boswellia 300 mg 3×/day for 6 weeks improved symptoms and lung function in 70% vs 27% on placebo. The mechanism (5-lipoxygenase inhibition) is biologically plausible for the leukotriene pathway in asthma. Subsequent larger trials are sparse; modern asthma guidelines don't include boswellia.
Bottom line: Possibly helpful, but the trial base is small. Keep your inhaled controller and discuss adjuncts with your pulmonologist.
Radiation-induced cerebral edema (brain tumors)
Disease adjunctKirste et al., 2011 RCT in 44 brain-tumor patients receiving radiotherapy: Boswellia serrata extract 4,200 mg/day reduced cerebral edema by ≥75% in 60% of treated vs 26% of placebo (as measured on imaging). This is one of the few botanical interventions evaluated in oncology supportive care with a positive RCT, but the trial is small and from a single center. MSKCC About Herbs lists it under purported uses.
Bottom line: An evidence-supported adjunctive option for radiation-induced cerebral edema, but only as part of an oncology-supervised plan.
Rheumatoid arthritis
Disease adjunctSmall trials of boswellia in rheumatoid arthritis (often combined with curcumin, ginger, or ashwagandha) suggest modest symptom relief, but as monotherapy results have been inconsistent. Modern RA care relies on DMARDs and biologics; boswellia is at best an adjunct for symptomatic relief.
Bottom line: Don't substitute for DMARDs. Possibly useful as a tolerability-friendly add-on.
How it works
How to take it
What to track
Bottom line: Standardized extract 300 mg 2–3×/day or AKBA-enriched 100–250 mg/day with food. Evaluate at 4–8 weeks; if no benefit, stop.
4 commercial forms
Compare the main delivery options and what they’re best suited for.
Standardized Boswellia serrata extract
Most studiedThe traditional gum-resin extract standardized to 60–75% boswellic acids. Used in most clinical trials at 300 mg 2–3× daily for OA. Generally well tolerated; AKBA content varies widely between brands.
Standard; effective at 600–900 mg/day in divided doses.
AKBA-enriched extract (5-Loxin, AprèsFlex / Aflapin)
Higher potencyStandardized to 20–30% 3-O-acetyl-11-keto-β-boswellic acid (AKBA), the most pharmacologically active boswellic acid. Studied at 100–250 mg/day for OA with faster onset (day 7 in Sengupta 2008).
Higher AKBA per dose; faster onset reported.
Boswellia phytosome (e.g., Casperome)
Enhanced absorptionBoswellic acids complexed with phospholipids to improve absorption. Preclinical and pilot studies suggest higher plasma boswellic-acid levels at lower doses; head-to-head clinical superiority over standard extracts is not firmly established.
Higher bioavailability claimed; clinical superiority unproven.
Raw gum resin / powder
TraditionalGround Boswellia serrata oleo-gum-resin, used in Ayurveda. Less consistent dosing than standardized extracts; potential for higher contaminant load and gastric bezoar with prolonged high-dose use.
Variable potency; not preferred for daily clinical use.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Boswellia inhibits platelet aggregation in vitro and may increase bleeding risk when combined with warfarin, DOACs, antiplatelet agents, or before surgery — stop 1–2 weeks before elective procedures.
Rare reports of hepatotoxicity and skin reactions; case report of gastric bezoar formation with chronic high-dose frankincense ingestion in a teenager with celiac disease.
Boswellia and AKBA inhibit P-glycoprotein and may modulate OATP1B3 and MRP2 transporters in vitro; clinical relevance unknown but could affect levels of substrate drugs.
Who should avoid it
- People on warfarin, DOACs (apixaban, rivaroxaban, dabigatran), or antiplatelet drugs (clopidogrel) without medical supervision.
- People on critical CYP3A4 substrate medications such as tacrolimus or some chemotherapy without checking with their pharmacist or oncologist.
- Pregnant or breastfeeding people — safety data lacking and traditional Ayurvedic texts cautioned against use.
- People with known allergy to frankincense, myrrh, or other resins.
Pregnancy & breastfeeding
Avoid during pregnancy and breastfeeding — safety data are lacking and traditional Ayurvedic literature cautioned against use in pregnancy. There is no compelling clinical reason to use boswellia during pregnancy.
Bottom line: Generally well tolerated for short- and medium-term use. Main cautions are bleeding risk on anticoagulants, possible CYP/transporter interactions, and avoidance in pregnancy.
Interactions
Boswellia inhibits platelet aggregation in vitro — added bleeding risk when combined with anticoagulants or antiplatelets. Stop 1–2 weeks before surgery.
AKBA inhibits CYP3A4 and P-glycoprotein in vitro; could theoretically raise levels of narrow-therapeutic-index drugs. Check with your pharmacist.
Boswellia may modulate immune pathways (NF-κB) — combining with immunosuppressants in IBD or RA hasn't been well-studied. Discuss with your specialist before adding.
Both inhibit inflammatory pathways and may have additive analgesic and bleeding effects. Often used together intentionally for OA pain; monitor for GI and bleeding side effects.
A 2024 meta-analysis suggested boswellia modestly improves glycemic markers in type 2 diabetes; could theoretically add to glucose-lowering effects. Monitor blood sugars if combining.
Documented interactions
Evidence-graded pair pages with sources, dosing notes, and timing guidance — a complement to the narrative section above.
Beneficial pairs (2)
+ omega-3
synergyBoswellic acids inhibit 5-lipoxygenase to reduce pro-inflammatory leukotrienes, while EPA and DHA from omega-3s lower the arachidonic acid available to inflammatory enzymes and serve as substrates for specialized pro-resolving mediators (resolvins, protectins) that help switch inflammation off. The two act at different steps of the same lipid cascade, giving complementary anti-inflammatory coverage. Evidence in joint pain is modest but consistent.
+ curcumin
synergyCurcumin and boswellia act on complementary anti-inflammatory pathways (NF-kB/prostaglandins and 5-LOX/leukotrienes), and a randomized placebo-controlled trial found the combination eased knee osteoarthritis symptoms more than curcumin alone.
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is Boswellia the same as frankincense?⌄
Yes. Boswellia is the genus that produces frankincense resin. Indian frankincense (Boswellia serrata) is the most commonly used species in supplements.
How does it compare to NSAIDs for joint pain?⌄
Boswellia works through a different mechanism (5-LOX inhibition rather than COX inhibition). Effects are typically more modest than NSAIDs but with a better GI and cardiovascular safety profile.
How long until I notice results?⌄
Joint pain improvements typically develop over 4 to 8 weeks of consistent daily use. Subjective benefits may begin earlier.
Should I combine Boswellia with turmeric?⌄
Many joint products combine Boswellia with turmeric/curcumin. They work through different anti-inflammatory pathways, and combinations may offer broader effects. Direct evidence for the combination versus single ingredients is limited.
Is Boswellia safe in pregnancy?⌄
No. Boswellia may stimulate uterine activity and theoretically promote menstruation. It should be avoided during pregnancy.
References by claim
Track Boswellia with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.